Showing results (31-40 of 98) with videos related to
Sort By:
Pageof 10
British Journal of Haematology|February 26, 2026
Immune-related adverse events in the treatment of Hodgkin lymphoma with immune checkpoint inhibitorsLisa Argnani, Vittorio Stefoni, Beatrice Casadei, et al.Expert Review of Clinical Immunology|February 19, 2026
Skin toxicities related to Bruton tyrosine kinase inhibitors: an updated reviewStephano Cedirian, Vito Epifani, Gianluca Cafasso, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 17, 2025
Semiquantitative PET Parameters Refine Prognosis in CAR T-Treated Lymphoma After 1 and 3 Months: A Prospective Single-Center StudyAndrea Farolfi, Beatrice Casadei, Claudio Malizia, et al.Journal of Cancer Research and Clinical Oncology|March 3, 2022
BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experienceVittorio Stefoni, Lisa Argnani, Matteo Carella, et al.Journal of Neurology|January 30, 2026
Prospective observational study of magnetic resonance imaging in anti-CD19 CAR T-cell-associated neurotoxicityGian Maria Asioli, Federica Pondrelli, Luca Spinardi, et al.Methods (San Diego, Calif.)|March 10, 2025
Two minimally invasive strategies to implant guide cannulas for multiple injections in deep brain areasStefania Bartoletti, Federica Raimondi, Beatrice Casadei Garofani, et al.Annals of Hematology|December 11, 2020
Treatment and outcomes of primary mediastinal B cell lymphoma: a three-decade monocentric experience with 151 patientsBeatrice Casadei, Lisa Argnani, Alice Morigi, et al.Hematological Oncology|September 9, 2020
Potential survival benefit for patients receiving autologous hematopoietic stem cell transplantation after checkpoint inhibitors for relapsed/refractory Hodgkin lymphoma: A real-life experienceBeatrice Casadei, Lisa Argnani, Alice Morigi, et al.Genes, Chromosomes & Cancer|July 3, 2020
Generation of pralatrexate resistant T-cell lymphoma lines reveals two patterns of acquired drug resistance that is overcome with epigenetic modifiersLuigi Scotto, Cristina Kinahan, Beatrice Casadei, et al.Pharmaceutics|March 29, 2023
Does Cytokine-Release Syndrome Induced by CAR T-Cell Treatment Have an Impact on the Pharmacokinetics of Meropenem and Piperacillin/Tazobactam in Patients with Hematological Malignancies? Findings from an Observational Case-Control StudyChun Liu, Pier Giorgio Cojutti, Maddalena Giannella, et al.Pageof 10